Aerovate Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	614	626	721	288	-	-
Market Cap Growth	-	-13.15%	150.50%	-	-	-
Enterprise Value	493	504	593	121	-5	-1
PE Ratio	-8.29	-8.29	-14.00	-12.53	-	-
PB Ratio	5.61	5.72	5.69	1.67	-	-
P/FCF Ratio	-11.00	-11.00	-18.34	-10.44	-	-
P/OCF Ratio	-11.03	-11.03	-18.43	-10.50	-	-
EV/EBITDA Ratio	-6.69	-6.69	-11.53	-5.27	0.48	0.30
EV/EBIT Ratio	-6.68	-6.68	-11.51	-5.27	0.48	0.30
EV/FCF Ratio	-8.86	-8.86	-15.08	-4.39	0.58	0.36
Debt / Equity Ratio	0.01	0.01	0.01	0.00	-	-0.69
Debt / EBITDA Ratio	-0.01	-0.01	-0.02	-0.03	-	-0.75
Debt / FCF Ratio	-0.01	-0.01	-0.03	-0.02	-	-0.90
Quick Ratio	6.94	6.94	16.60	65.64	2.58	5.35
Current Ratio	7.04	7.04	16.90	68.37	2.64	5.35
Interest Coverage	-	-	-	-	-127.15	-
Return on Equity (ROE)	-61.60%	-61.60%	-35.60%	-29.20%	113.20%	-
Return on Assets (ROA)	-55.10%	-55.10%	-34.00%	-21.30%	-233.60%	-
Return on Capital (ROIC)	-73.92%	-73.92%	-41.65%	-13.31%	66.61%	291.34%
Earnings Yield	-12.29%	-12.06%	-7.15%	-7.98%	-	-
FCF Yield	-9.26%	-9.09%	-5.45%	-9.58%	-	-
Buyback Yield / Dilution	-7.60%	-7.60%	-99.06%	-4975.15%	67.70%	-
Total Shareholder Return	-7.60%	-7.60%	-99.06%	-4975.15%	67.70%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).